Eczema Market Report 2026

The eczema market size has grown strongly in recent years. It will grow from $17.76 billion in 2025 to $19.21 billion in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to atopic dermatitis prevalence, allergen exposure increase, dermatology clinic growth, steroid therapy usage, skincare awareness.

The eczema market size is expected to see strong growth in the next few years. It will grow to $25.98 billion in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to targeted biologics adoption, personalized dermatology treatments, digital dermatology platforms, pediatric care expansion, lifestyle-related flare management. Major trends in the forecast period include increasing use of biologic therapies, growing demand for topical non-steroidal treatments, rising awareness of chronic skin conditions, expansion of pediatric eczema management, improved focus on long-term disease control.

The rising prevalence of autoimmune disorders is expected to drive the growth of the eczema market in the coming years. Autoimmune disorders occur when the body’s immune system mistakenly attacks its own healthy cells, tissues, or organs, causing inflammation and damage. This increase is linked to genetic predisposition, environmental influences, infections, dietary changes, and lifestyle factors such as stress and pollutant exposure. Autoimmune diseases like psoriasis, lupus, and rheumatoid arthritis are associated with dysregulated immune responses, which make individuals more prone to eczema and other inflammatory skin conditions. For instance, in February 2024, according to Arthritis Australia, a non-profit organization based in Australia, it is projected that in 2025 approximately 212,136 males and 362,137 females will have rheumatoid arthritis (RA), with these numbers expected to rise by 2040 to about 280,040 males and 479,828 females. Therefore, the increasing prevalence of autoimmune disorders is fueling the growth of the eczema market.

Companies in the eczema market are increasingly focusing on developing innovative products, such as eczema care creams, to improve treatment outcomes and meet consumer demand for advanced skincare solutions. Eczema care creams are specialized formulations designed to soothe, hydrate, and protect skin affected by eczema, helping to reduce itching, inflammation, and dryness. For example, in September 2024, Dove, a UK-based personal care brand, launched a new Baby Dove Eczema Care range, including the Baby Dove Eczema Care Soothing Bath Treatment and Baby Dove Eczema Care Cream. These products are tailored for infants with eczema, formulated with 100% skin-natural nutrients, and contain 1% colloidal oatmeal, a key ingredient for calming irritation and maintaining skin moisture.

In May 2024, Johnson & Johnson, a US-based pharmaceutical company, acquired Proteologix Inc. for approximately $850 million. Through this acquisition, Johnson & Johnson aims to strengthen its leadership in atopic dermatitis (AD) and asthma treatments by incorporating innovative bispecific antibody therapies into its portfolio. Proteologix Inc. is a US-based biotechnology company that specializes in developing bispecific antibodies for immune-mediated diseases.

Major companies operating in the eczema market are Pfizer Inc., AbbieVie Inc., Bayer AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Amgen, Hoffmann-La Roche AG, Eli Lilly and Co., Siemens Healthineers AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc, Bausch Health Companies Inc., Galderma, Cadila Pharmaceuticals Ltd., LEO Pharma A/S, Almirall, Kyowa Kirin, Alliance Pharma Plc, Encore Dermatology Inc., Arcutis Inc.

North America was the largest region in the eczema market in 2025. The regions covered in the eczema market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the eczema market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the eczema market by increasing costs of imported biologics, topical formulations, and dermatology devices. Hospitals and dermatology centers are most affected due to reliance on specialty drugs. These tariffs raise treatment costs by increasing pricing of advanced biologics and prescription dermatological therapies, impacting long-term disease management and patient adherence. However, they encourage domestic dermatological drug manufacturing, supporting regional production of topical agents and specialty treatments to reduce reliance on imported biologics.

The eczema market research report is one of a series of new reports that provides eczema market statistics, including eczema industry global market size, regional shares, competitors with a eczema market share, detailed eczema market segments, market trends and opportunities, and any further data you may need to thrive in the eczema industry. This eczema market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Eczema is a chronic inflammatory skin disorder marked by redness, itching, dryness, and irritation. It arises from genetic and environmental factors, leading to a weakened skin barrier and an overactive immune response. Eczema can affect individuals of all ages, though it is more common in children, and often occurs in flare-ups triggered by allergens, irritants, stress, or changes in climate.

The main types of eczema include atopic dermatitis, contact dermatitis, seborrheic dermatitis, and others. Atopic dermatitis is a chronic skin condition characterized by itchy, red, and inflamed skin, frequently triggered by allergens, irritants, or stress. Treatments for eczema include topical therapies, oral medications, biologics, and phototherapy. The condition affects children, adults, and the elderly and is managed by end users such as hospitals, clinics, dermatology centers, home care providers, and pharmacies.

The eczema market consists of revenues earned by entities by providing services such as diagnosis and consultation services, prescription and medication services, phototherapy services, allergy testing and immunotherapy, and skin barrier repair therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The eczema market also includes sales of antihistamines, topical corticosteroids, calcineurin inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.